Skip to main content
Top
Published in: BMC Musculoskeletal Disorders 1/2012

Open Access 01-12-2012 | Research article

Incidence and prevalence of idiopathic inflammatory myopathies among commercially insured, Medicare supplemental insured, and Medicaid enrolled populations: an administrative claims analysis

Authors: Karen E Smoyer-Tomic, Anthony A Amato, Ancilla W Fernandes

Published in: BMC Musculoskeletal Disorders | Issue 1/2012

Login to get access

Abstract

Background

Idiopathic inflammatory myopathies (IIMs) are a rare group of autoimmune syndromes characterized by chronic muscle inflammation and muscle weakness with no known cause. Little is known about their incidence and prevalence. This study reports the incidence and prevalence of IIMs among commercially insured and Medicare and Medicaid enrolled populations in the US.

Methods

We retrospectively examined medical claims with an IIM diagnosis (ICD-9-CM 710.3 [dermatomyositis (DM)], 710.4 [polymyositis (PM)], 728.81[interstitial myositis]) in the MarketScan® databases to identify age- and gender-adjusted annual IIM incidence and prevalence for 2004–2008. Sensitivity analysis was performed for evidence of a specialist visit (rheumatologist/ neurologist/dermatologist), systemic corticosteroid or immunosuppressant use, or muscle biopsy.

Results

We identified 2,990 incident patients between 2004 and 2008 (67% female, 17% Medicaid enrollees, 27% aged ≥65 years). Overall adjusted IIM incidence for 2004–2008 for commercial and Medicare supplemental groups combined were 4.27 cases (95% CI, 4.09-4.44) and for Medicaid, 5.23 (95% CI 4.74-5.72) per 100,000 person-years (py). Disease sub-type incidence rates per 100,000-py were 1.52 (95% CI 1.42-1.63) and 1.70 (1.42-1.97) for DM, 2.46 (2.33-2.59) and 3.53 (3.13-3.94) for PM, and 0.73 (0.66-0.81) and 0.78 (0.58-0.97) for interstitial myositis for the commercial/Medicare and Medicaid cohorts respectively. Annual incidence fluctuated over time with the base MarketScan populations. There were 7,155 prevalent patients, with annual prevalence ranging from 20.62 to 25.32 per 100,000 for commercial/Medicare (83% of prevalent cases) and from 15.35 to 32.74 for Medicaid.

Conclusions

We found higher IIM incidence than historically reported. Employer turnover, miscoding and misdiagnosing, care seeking behavior, and fluctuations in database membership over time can influence the results. Further studies are needed to confirm the incidence and prevalence of IIM.
Appendix
Available only for authorised users
Literature
2.
go back to reference Prieto S, Grau JM: The geoepidemiology of autoimmune muscle disease. Autoimmun Rev. 2010, 9: A330-4. 10.1016/j.autrev.2009.11.006.CrossRefPubMed Prieto S, Grau JM: The geoepidemiology of autoimmune muscle disease. Autoimmun Rev. 2010, 9: A330-4. 10.1016/j.autrev.2009.11.006.CrossRefPubMed
3.
go back to reference Amato AA, Barohn RJ: Inclusion body myositis: old and new concepts. J Neurol Neurosurg Psychiatry. 2009, 80: 1186-93. 10.1136/jnnp.2009.173823.CrossRefPubMed Amato AA, Barohn RJ: Inclusion body myositis: old and new concepts. J Neurol Neurosurg Psychiatry. 2009, 80: 1186-93. 10.1136/jnnp.2009.173823.CrossRefPubMed
4.
go back to reference Amato AA, Barohn RJ: Evaluation and treatment of inflammatory myopathies. J Neurol Neurosurg Psychiatry. 2009, 80: 1060-1068. 10.1136/jnnp.2008.169375.CrossRefPubMed Amato AA, Barohn RJ: Evaluation and treatment of inflammatory myopathies. J Neurol Neurosurg Psychiatry. 2009, 80: 1060-1068. 10.1136/jnnp.2008.169375.CrossRefPubMed
5.
go back to reference Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR: 119th ENMC international workshop.Trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The Netherlands. Neuromuscul Disord. 2004, 14: 337-345. 10.1016/j.nmd.2004.02.006.CrossRefPubMed Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR: 119th ENMC international workshop.Trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The Netherlands. Neuromuscul Disord. 2004, 14: 337-345. 10.1016/j.nmd.2004.02.006.CrossRefPubMed
6.
go back to reference Pongratz D, Späth M, Fischer P: Myositis as a cause of muscle pain. J Musculoskeletal Pain. 1999, 7: 121-129. 10.1300/J094v07n01_12.CrossRef Pongratz D, Späth M, Fischer P: Myositis as a cause of muscle pain. J Musculoskeletal Pain. 1999, 7: 121-129. 10.1300/J094v07n01_12.CrossRef
7.
go back to reference Mammen AL: Dermatomyositis and poly myositis: Clinical presentation, autoantibodies, and pathogenesis. Ann NY Acad Sci. 2010, 1184: 34-153.CrossRef Mammen AL: Dermatomyositis and poly myositis: Clinical presentation, autoantibodies, and pathogenesis. Ann NY Acad Sci. 2010, 1184: 34-153.CrossRef
8.
go back to reference Mastaglia FL, Phillips BA: Idiopathic inflammatory myopathies: Epidemiology, classification, and diagnostic criteria. Rheum Dis Clin North Am. 2002, 28: 723-741. 10.1016/S0889-857X(02)00021-2.CrossRefPubMed Mastaglia FL, Phillips BA: Idiopathic inflammatory myopathies: Epidemiology, classification, and diagnostic criteria. Rheum Dis Clin North Am. 2002, 28: 723-741. 10.1016/S0889-857X(02)00021-2.CrossRefPubMed
9.
go back to reference Hengstman GJD, van den Hoogen FHJ, van Engelen BGM: Treatment of the inflammatory myopathies: Update and practical recommendations. Expert Opin. Pharmacother. 2009, 10: 1183-1190. 10.1517/14656560902913815.CrossRefPubMed Hengstman GJD, van den Hoogen FHJ, van Engelen BGM: Treatment of the inflammatory myopathies: Update and practical recommendations. Expert Opin. Pharmacother. 2009, 10: 1183-1190. 10.1517/14656560902913815.CrossRefPubMed
10.
go back to reference Wilson FC, Ytterberg SR, St Sauver JL, Reed AM: Epidemiology of sporadic inclusion body myositis and polymyositis in Olmsted County, Minnesota. J Rheumatol. 2008, 35: 445-7.PubMed Wilson FC, Ytterberg SR, St Sauver JL, Reed AM: Epidemiology of sporadic inclusion body myositis and polymyositis in Olmsted County, Minnesota. J Rheumatol. 2008, 35: 445-7.PubMed
11.
go back to reference Briani C, Doria A, Sarzi- Puttini P, Dalakas MC: Update on idiopathic inflammatory myopathies. Autoimmunity. 2006, 39: 161-170. 10.1080/08916930600622132.CrossRefPubMed Briani C, Doria A, Sarzi- Puttini P, Dalakas MC: Update on idiopathic inflammatory myopathies. Autoimmunity. 2006, 39: 161-170. 10.1080/08916930600622132.CrossRefPubMed
12.
go back to reference Dalakas MC, Hohlfeld R: Polymyositis and dermatomyositis. Lancet. 2003, 362: 971-82. 10.1016/S0140-6736(03)14368-1.CrossRefPubMed Dalakas MC, Hohlfeld R: Polymyositis and dermatomyositis. Lancet. 2003, 362: 971-82. 10.1016/S0140-6736(03)14368-1.CrossRefPubMed
13.
go back to reference Choy EHS, Isenberg DA: Treatment of dermatomyositis and polymyositis. Rheumatology. 2002, 41: 7-13.CrossRefPubMed Choy EHS, Isenberg DA: Treatment of dermatomyositis and polymyositis. Rheumatology. 2002, 41: 7-13.CrossRefPubMed
14.
go back to reference Oddis CV, Conte CG, Steen VD, Medsger JA: Incidence of polymyositis- dermatomyositis. J Rheumatol. 1990, 17: 1329-34.PubMed Oddis CV, Conte CG, Steen VD, Medsger JA: Incidence of polymyositis- dermatomyositis. J Rheumatol. 1990, 17: 1329-34.PubMed
15.
go back to reference Benbassat J, Geffel D, Zlotnick A: Epidemiology of polymyositis-dermatomyositis in Israel, 1960–76. Isr J Med Sci. 1980, 16: 197-200.PubMed Benbassat J, Geffel D, Zlotnick A: Epidemiology of polymyositis-dermatomyositis in Israel, 1960–76. Isr J Med Sci. 1980, 16: 197-200.PubMed
16.
go back to reference Bernatsky S, Joseph L, Pineau CA, Belisle CA, Boivin JF, Banerjee D, Clarke AE: Estimating the prevalence of polymyositis and dermatomyositis from administrative data: age, sex and regional differences. Ann Rheum Dis. 2009, 68: 1192-96. 10.1136/ard.2008.093161.CrossRefPubMed Bernatsky S, Joseph L, Pineau CA, Belisle CA, Boivin JF, Banerjee D, Clarke AE: Estimating the prevalence of polymyositis and dermatomyositis from administrative data: age, sex and regional differences. Ann Rheum Dis. 2009, 68: 1192-96. 10.1136/ard.2008.093161.CrossRefPubMed
17.
go back to reference Cooper GS, Stroehla BC: The epidemiology of autoimmune diseases. Autoimmun Rev. 2003, 2: 119-125. 10.1016/S1568-9972(03)00006-5.CrossRefPubMed Cooper GS, Stroehla BC: The epidemiology of autoimmune diseases. Autoimmun Rev. 2003, 2: 119-125. 10.1016/S1568-9972(03)00006-5.CrossRefPubMed
18.
go back to reference Bendewald MJ, Wetter DA, Li X, Davis M: Incidence of dermatomyositis and clinically amyopathic dermatomyositis. Arch Dermatol. 2010, 146: 26-30. 10.1001/archdermatol.2009.328.CrossRefPubMed Bendewald MJ, Wetter DA, Li X, Davis M: Incidence of dermatomyositis and clinically amyopathic dermatomyositis. Arch Dermatol. 2010, 146: 26-30. 10.1001/archdermatol.2009.328.CrossRefPubMed
19.
go back to reference Furst DE, Amato AA, Iorga SR, Gajira K, Fernandes A: Epidemiology of idiopathic inflammatory myopathy in a large United States managed care population [abstract]. Arthritis Rheum. 2011, 63: S726- Furst DE, Amato AA, Iorga SR, Gajira K, Fernandes A: Epidemiology of idiopathic inflammatory myopathy in a large United States managed care population [abstract]. Arthritis Rheum. 2011, 63: S726-
20.
go back to reference Insinga RA, Itzeler RF, Pellissier JM, Saddier P, NIkas AA: The incidence of herpes zoster in a United States administrative datablase. J Gen Intern Med. 2005, 20: 748-753. 10.1111/j.1525-1497.2005.0150.x.CrossRefPubMedPubMedCentral Insinga RA, Itzeler RF, Pellissier JM, Saddier P, NIkas AA: The incidence of herpes zoster in a United States administrative datablase. J Gen Intern Med. 2005, 20: 748-753. 10.1111/j.1525-1497.2005.0150.x.CrossRefPubMedPubMedCentral
Metadata
Title
Incidence and prevalence of idiopathic inflammatory myopathies among commercially insured, Medicare supplemental insured, and Medicaid enrolled populations: an administrative claims analysis
Authors
Karen E Smoyer-Tomic
Anthony A Amato
Ancilla W Fernandes
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Musculoskeletal Disorders / Issue 1/2012
Electronic ISSN: 1471-2474
DOI
https://doi.org/10.1186/1471-2474-13-103

Other articles of this Issue 1/2012

BMC Musculoskeletal Disorders 1/2012 Go to the issue